Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells
Open Access
- 21 July 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (7) , 1761
Abstract
Pancreatic adenocarcinoma is one of the leading causes of cancer-related death in developed countries. Only 15% of patients are candidates for radical surgery, and adequate prognostication may guide proper postsurgical management. We aimed to retrospectively assess the prognostic significance of the immunohistochemical expression of immune checkpoint receptors (PD-L1 and VISTA), markers of systemic inflammation, thrombosis in the tumor area, and the tumor budding in the group of 107 patients diagnosed with pancreatic adenocarcinoma in a single center. The high expression of PD-L1 on tumor cells (TCs) was associated with worse overall survival (OS, p = 0.041, log-rank). On the contrary, high PD-L1 or VISTA on tumor-associated immune cells (TAICs) was correlated with better OS (p = 0.006 and p = 0.008, respectively, log-rank). The joint status of PD-L1 on TCs and TAICs stratified patients into three prognostic groups. The cases with high-grade budding were characterized by higher PD-L1 expression on TCs (p = 0.008) and elevated systemic inflammatory markers. Moreover, budding was identified as the independent prognostic factor in multivariate Cox regression analysis (HR = 2.87; 95% CI = 1.75–4.68; p < 0.001). To conclude, the pattern of PD-L1 and VISTA expression was associated with survival in univariate analysis. Tumor budding accurately predicts outcomes in pancreatic cancer and should be incorporated into routine histopathological practice.Keywords
Funding Information
- Medical University of Gdańsk (02-0095/07/267)
This publication has 46 references indexed in Scilit:
- PD-1/PD-L1 and immunotherapy for pancreatic cancerCancer Letters, 2017
- Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016Laboratory Investigation, 2017
- PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal CancerCellular Physiology and Biochemistry, 2017
- Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour modelOncotarget, 2016
- Starved and Asphyxiated: How Can CD8+ T Cells within a Tumor Microenvironment Prevent Tumor ProgressionFrontiers in Immunology, 2016
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responsesProceedings of the National Academy of Sciences, 2015
- Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic CancerAnnals of Surgical Oncology, 2014
- Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigenNature Immunology, 2013
- Tumour budding is a strong and independent prognostic factor in pancreatic cancerEuropean Journal of Cancer, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012